|Bid||133.50 x 500|
|Ask||133.98 x 500|
|Day's Range||126.40 - 133.71|
|52 Week Range||94.42 - 133.71|
|PE Ratio (TTM)||49.88|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.
In 2016, Celgene’s (CELG) Otezla generated revenues of around $1.0 billion, a 116% year-over-year (or YoY) increase.
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.